Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Cyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib (CYC202 or R-roscovitine) is a potent CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies. Here we studied the in vitro cytotoxic activity of seliciclib against multiple myeloma (MM) cells. Our data demonstrate that seliciclib has potent cytotoxicity against MM cells that are both sensitive and resistant to conventional therapy as well as primary MM cells from patients. Cell-cycle and Western blot analysis confirmed apoptosis. Importantly, seliciclib triggered a rapid down-regulation of Mcl-1 transcription and protein expression independent of caspase cleavage. Adherence of MM cells to bone marrow stromal cells (BMSCs) induced increased Mcl-1 expression associated with signal transducer and activator of transcription 3 (STAT3) phosphorylation, which was inhibited in a time- and dose-dependent manner by seliciclib. Furthermore, seliciclib inhibited interleukin 6 (IL-6) transcription and secretion triggered by tumor cell binding to BMSCs. Up-regulation of Mcl-1 expression in cocultures was only partially blocked by neutralizing antibody to IL-6, suggesting alternative mechanisms of Mcl-1 modulation by seliciclib. Finally, combination studies of seliciclib with doxorubicin and bortezomib show in vitro synergism, providing the rationale for testing these drug combinations to improve patient outcome in MM.

[1]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[2]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[3]  D. Carrasco,et al.  Identification of genes modulated in multiple myeloma using genetically identical twin samples. , 2004, Blood.

[4]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[6]  K. Podar,et al.  Mcl-1 Regulation and Its Role in Multiple Myeloma , 2004, Cell cycle.

[7]  M. Amiot,et al.  1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS , 2004 .

[8]  A. Senderowicz.  Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials , 2003, Cancer biology & therapy.

[9]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[10]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[11]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[12]  Bin Zhang,et al.  IL-6-independent expression of Mcl-1 in human multiple myeloma , 2003, Oncogene.

[13]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[14]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[15]  N. Munshi,et al.  NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.

[16]  R. Bataille,et al.  Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.

[17]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[18]  Z. Estrov,et al.  Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis , 2004 .

[19]  T. David-Pfeuty.  Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells , 1999, Oncogene.

[20]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[21]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[22]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[23]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[24]  N. Raje,et al.  Thalidomide and immunomodulatory drugs as cancer therapy. , 2002, Current opinion in oncology.

[25]  D. Wong,et al.  Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. , 2002, International journal of oncology.

[26]  R. Bataille,et al.  Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl‐1 anti‐apoptotic molecule , 2001, British journal of haematology.

[27]  S. Grant,et al.  Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process , 2003, Oncogene.

[28]  R. Pestell,et al.  Cell cycle regulation and RNA polymerase II. , 2000, Frontiers in bioscience : a journal and virtual library.

[29]  Paul Richardson,et al.  Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.

[30]  P. Fischer,et al.  CDK inhibitors in clinical development for the treatment of cancer , 2003, Expert opinion on investigational drugs.

[31]  R. Jove,et al.  Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. , 2003, Cancer research.

[32]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[33]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[34]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[35]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[37]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[38]  Paul Workman,et al.  The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway , 2004, Cancer Research.

[39]  C. Peschel,et al.  Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.

[40]  D. Lane,et al.  Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. , 2004, Chemistry & biology.

[41]  Y. Shima,et al.  Isolation and characterization of human multiple myeloma cell enriched populations. , 2000, Journal of immunological methods.